Google Scholar Profile
2025 - University of Calgary
Fletcher J, Manns B, Campbell D, Beall R (2025). Pharmacare is now law in Canada, but negotiations with provinces could slow progress. The Conversation.
Beall R, Flores Anato J, D’Souza A, Velásquez García H, Ma H, Baral S, Cabaj J, Cooper E, Hollis A, Janjua N, Katz A, Leal J, Maheu-Giroux M, Rennert May E, Malikov K, Mishra S, Moloney G, Yang F, Williamson T. (2025). A Canadian multi-province study of COVID-19 vaccine coverage along area-level social determinants in 2021. Public Health in Practice.
Quach A, Yohannes S, Olstad D, Campbell D, Corrigan C, Beall R. (2025) An environmental scan of financial incentives to increase access to healthy foods among adults: How, how much, and how often? BMC Public Health
Memedovich A, Steele B, Orr T, Chaudhry S, Tadrous M, Hollis A, Beall R (2025). Predicting drug patent challenges in the United States. PLoS Medicine.
Memedovich A, Steele B, Orr T, Hollis A, Salmon C, Hu J, Zinszer K, Williamson T, Beall R (2025). Applying a diffusion of innovations framework to characterize diffusion groups and more effectively to reach late adopters: COVID-19 vaccinations in 2021. BMJ Public Health.
2024 - University of Calgary
Liu K, Rennert-May E, Zhang Z, D'Souza A, Crocker A, Williamson T, Beall R, Leal J (2024). Evaluation of In-Hospital and Community-Based Healthcare Utilization and Costs using the Alberta COVID-19 Analytics and Research Database (ACARD): A Population-Based Descriptive Study. Health Services Insights.
Wouters O, Vogel M, Feldman W, Beall R, Kesselheim A, Tu S (2024). Differential legal protections for biologics vs small-molecule drugs in the US. JAMA.
Memedovich A, Orr T, Hollis A, Salmon C, Hu J, Zinszer K, Williamson T, Beall R (2024). Social network risk factors and COVID-19 vaccination: A cross-sectional survey study. Vaccine.
Newton J, Riazi R, Vashist N, Jarvis H, Lang E, Clement F, Beall R (2024). Solutions for patients visiting the emergency department with non-emergent issues: Results from a deliberative public policy analysis process. Internal and Emergency Medicine.
Fichadiya A, Quinn A, Au F, Campbell D, Lau D, Ronksley P, Beall R, Campbell DLT , Wilton S, Chew D (2024). Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. EP Europace.
Memedovich A, Farkas B, Hollis A, Salmon C, Hu J, Zinszer K, Williamson T, Beall R (2024). COVID-19 vaccine speed-to-market and vaccine hesitancy: A cross-sectional survey study. Healthcare Policy.
Tariq S, Olstad DL, Beall R, Spackman E, Lipscombe L, Dunn S, Lashewicz B, Elliott M, Campbell DJT (2024). Exploring the prospective acceptability of a healthy food incentive program from the perspective of people with type 2 diabetes and experiences of household food insecurity in Alberta, Canada. Public Health Nutrition.
2023 - University of Calgary
Eagles M, Beall R, Ben-Israel D, Wong J, Hill M, Spackman E (2023). Neighbourhood deprivation, distance to nearest comprehensive stroke centre and access to endovascular thrombectomy for ischemic stroke: A population-based study. CMAJ Open.
Olsen A, Beall R, Knox R, Tu S, Kesselheim A, Feldman W (2023). Patents and Non-Patent Statutory Exclusivities on FDA-Approved Insulin Products, 1986-2019. PLOS Medicine.
Flores Anato J, Ma H, Hamilton M, Xia Y, Harper S, Buckeridge D, Brisson M, Hillmer M, Malikov K, Kerem A, Beall R, Baral S, Dubé E, Mishra S, Maheu-Giroux M. (2023). Impact of a vaccine passport on first-dose COVID-19 vaccine coverage by age and area-level social determinants in the Canadian provinces of Québec and Ontario: An interrupted time series analysis. CMAJ Open.
Alhiary R, Kesselheim A, Gabriele S, Beall R, Tu S, Feldman W (2023) Patents and regulatory exclusivities on GLP-1 receptor agonists, 2005-2021. JAMA.
Rennert-May E, Crocker A, D'Souza A, Zhang Z, Chew D, Beall R, Vickers D, Leal J (2023). Healthcare utilization and adverse outcomes stratified by sex, age and long-term care residency using the Alberta COVID-19 Analytics and Research Database (ACARD): A population-based descriptive study. BMC Infectious Diseases.
Steer K, Olstad D, Campbell D, Beall R, Caron-Roy S., Spackman E (2023). The impact of providing material benefits to improve access to food on clinical parameters, dietary intake, and household food insecurity in people with diabetes: A systematic review with narrative synthesis. Advances in Nutrition.
Reddy S, Beall R, Tu S, Kesselheim A, Feldman WB (2023). Patent Challenges And Litigation On Inhalers For Asthma And COPD. Health Affairs.
2022 - University of Calgary
Beall R, Glazer T, Ahmad H, Buell M, Hahn S, Houston A, Kesselheim A, Nickerson J, Kaplan W (2022). Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective. Healthcare Policy, 18(2): 14-26
Campbell DB, Campbell DJT, Au F, Beall R, Ronksley P, Chew DS, Ogundeji Y, Manns BJ, Hemmelgarn BR, Tonelli M, Quinn A. (2022) Patterns and patient characteristics associated with use of SGLT2 inhibitors among adults with type 2 diabetes: A population-based cohort study. Canadian Journal of Diabetes.
Beall RF, Leung AA, Quinn AE, Salmon C, Scory TD, Bresee LC, Ronksley PE (2022). Laboratory testing and antihypertensive medication adherence following initial treatment of incident, uncomplicated hypertension: A real-world data analysis. Journal of Clinical Hypertension.
Feldman WB, Bloomfield D, Beall RF, Kesselheim AS (2022). Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD. Nature Biotechnology.
Lau B, Tadrous M, Chu C, Hardcastle L, Beall R (2022). COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022. CMAJ.
Feldman W, Bloomfield D, Beall R, Kesselheim A (2022). Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986–2020. Health Affairs.
Wick J, Campbell D, McAlister F, Manns B, Tonelli M, Beall R, Hemmelgarn B, Stewart A, Ronksley P (2022). Identifying subgroups of adult high-cost health care users: a retrospective analysis. CMAJ Open.
Olstad DL, Beall R, Spackman E, Dunn S, Lipscombe L, Williams K, Oster R, Scott S, Zimmermann G, McBrien K, Steer K, Chan C. Tyminski S, Berkowitz S, Edwards A, Saunders-Smith T, Tariq S, Popeski N, White L, Williamson T, L’Abbe M, Raine K, Nejatinamini S, Naser A, Basualdo-Hammond C, Norris C, O’Connell P, Seidel J, Cabaj J, Campbell D. (2022) Healthy food prescription incentive programme for adults with type 2 diabetes who are experiencing food insecurity: protocol for a randomised controlled trial, modelling and implementation studies. BMJ Open.
Van de Wiele V, Beall R, Kesselheim A, Sarpatwari A (2022). The characteristics of patents impacting availability of biosimilars. Nature Biotechnology.
2021 - University of Calgary
Beall R, Moradpour J, Hollis A (2021). The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies. PLOS One.
Beall R, Hollis A, Kesselheim A, Spackman E (2021). Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value-Based? Value in Health.
Campbell, DJT, Campbell, DB, Ogundeji, Y, Au F, Beall R, Ronksley P, Quinn A, Manns B, Hemmelgarn B, Tonelli M, Spackman E (2021). First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs. Diabetic Medicine.
Kannappan S, Darrow J, Kesselheim A, Beall RF (2021) The Timing of 30‐Month Stay Expirations and Generic Entry: A Cohort Study of First Generics, 2013‐2020. Clinical and Translational Science.
Beall R, Kesselheim A, Hollis A (2021). Pre-market development times for innovative vaccines - to what extent are the COVID-19 vaccines outliers? Clinical Infectious Diseases.
Gowda V, Beall R, Kesselheim A, Sarpatwari A (2021). Identifying potential prescription drug product hopping. Nature Biotechnology.
Quinn A, Ronksley P, Bresee L, Au F, Wick J, Leung A, McBrien K, Manns B, Beall R (2021). Antihypertensive prescribing for uncomplicated, incident hypertension: Opportunities for cost savings. Canadian Journal of Cardiology Open.
Sahragardjoonegani B, Beall R, Kesselheim A, Hollis A (2021). Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of Pharmaceutical Policy and Practice.
2020 - University of Calgary
Beall R, Hollis A (2020). Global clinical trial mobilization for COVID-19: higher, faster, stronger. Drug Discovery Today.
Hardcastle L, Beall R (2020). How coronavirus is contributing to drug shortages in Canada. The Conversation.
Beall R, Quinn A, Kesselheim A, Tessema F, Sarpatwari A (2020). Generic competition for drugs treating rare diseases. Journal of Law, Medicine, & Ethics.
Beall R, Ronksley P, Wick J, Darrow J, Sarpatwari A, Kesselheim A (2020). Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clinical Pharmacology & Therapeutics.
Darrow J, Beall R (2020). Expedited Regulatory Review of Low-Value Drugs. Healthcare Policy.
Dave C, Sinha M, Beall R, Kesselheim A (2020). Estimating the cost of delayed generic drug entry to Medicaid. Health Affairs.
2019 - University of Calgary
Beall R, Hardcastle L, Clement F, Hollis A (2019). How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada? Health Policy.
Baxi S, Beall R, Yang J, Mackey T (2019). A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications. Globalization and Health.
Beall R, Hwang T, Kesselheim A (2019). Pre-market development times for biologics versus small-molecule drugs. Nature Biotechnology.
Beall R, Darrow J, Kesselheim A (2019). Approximating Future Generic Entry for New Drugs. The Journal of Law, Medicine, and Ethics.
Houston A, Beall R (2019). Could the Paragraph 6 Compulsory License System be Revised to Increase Participation by the Generics Industry? Lessons Learned from an Unheralded and Unsuccessful Attempt to Use Canada’s Access to Medicines Regime. McGill Journal of Law and Health.
Memedovich KA, Manns B, Beall R, Hollis A, Clement F (2019). The impact of pharmaceutical rebates on patients’ drug expenditures. CMAJ.
Beall R, Hwang T, Kesselheim A (2019). Major events in the life course of new drugs. New England Journal of Medicine.
Beall R, Kesselheim A, Sarpatwari A (2019). New Drug Formulations and Their Respective Generic Entry Dates. Journal of Managed Care and Specialty Pharmacy.
Beall R, Darrow J, Kesselheim A (2019). Patent term restoration for top-selling drugs in the United States. Drug Discovery Today.
Darrow J, Beall R, Kesselheim A (2019). The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Applied Health Economics and Health Policy.
2017-2018 - PORTAL Fellowship
Beall R, Darrow J, Kesselheim A (2018). A method for approximating future entry of generic drugs. Value in Health.
Beall R, Kesselheim A (2018). Tertiary patenting on drug-device combination products in the United States. Nature Biotechnology.
Sarpatwari A, Beall R, Abdurrob A, He M, Kesselheim, A (2018). Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period. Health Affairs.
Darrow J, Beall R, Kesselheim A (2017). Will inter partes review speed US generic drug entry? Nature Biotechnology.
2012 & earlier - Graduate studies, University of Ottawa, PhD, & University of Denver, Masters
Beall R, Attaran A (2017) A method for understanding generic procurement of HIV medicines by developing countries with patent protection. Social Science and Medicine.
Beall R, Blanchet R, Attaran A (2017). In which developing countries are companies filing patents on essential medicines? Globalization and Health.
Wolfson M, & Beall R (2017). On the determinants of health inequalities – Explorations using the Theoretical Health Inequality Model. In: Growing Inequality: Bridging Complex Systems, Population Health and Health Disparities. George A. Kaplan, Ana V. Diez Roux, Carl P. Simon, Sandro Galea (eds). Westphalia Press: Washington, DC. goo.gl/sYyXqs
Beall R, Attaran A (2016) Which patent and where? Why international patent transparency for medicines is needed. Nature Biotechnology.
Beall R, Nickerson J, Kaplan W, Attaran A (2016) Is patent "evergreening" restricting access to medicine/device combination products? PLOS ONE.
Kaplan W, Beall R (2016). The global intellectual property ecosystem for insulin and its public health implications: an observational study. Journal of Pharmaceutical Policy and Practice.
Beall R, Schwalm JDR, Huffman MD, McCready T, Yusuf S, Attaran A (2016) Could patents interfere with the development of a cardiovascular polypill? Journal of Translational Medicine.
Houston A, Beall R, Attaran A (2016). Upstream solutions for price-gouging on critical generic medicines. Journal of Pharmaceutical Policy and Practice.
Attaran A, Beall R, Mackey T (2016). Lowering the High Cost of Cancer Drugs—III. Letter in response to Tefferi et al, ‘In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs,’ Mayo Clinic Proceedings. 91(3): 399–400.
Wolfson M, Gribble S, Beall R (2016) Exploring Contingent Inequalities – Building the Theoretical Health Inequality Model. (Book chapter) In Agent-based Modelling in Population Studies: Concepts, Methods, and Applications. André Grow and Jan Van Bavel (eds). Springer Series on Demographic Methods and Population Analysis.
Beall R, Attaran A (2016). (In)accuracy of using US and Canadian patent registers for determining medicines' patent status globally: A call for global patent transparency on essential and lifesaving medicines. United Nations Secretary-General High-level Panel on Access to Medicines
Kaplan W, Beall R (2016) Insulin patent profile. Health Action International, Amsterdam.
Beall R (2016). A policy brief - Clarifying the Debate on IP and Access: Patents and the 2013 WHO Model List of Essential Medicines. World Intellectual Property Organization, Geneva.
Beall R, Attaran A (2016). Which drugs on the World Health Organization’s Model List of Essential Medicines are patented in the developing world and where? A patent landscape study. World Intellectual Property Organization, Geneva.
Beall R, Kuhn R, Attaran A (2015) Compulsory Licensing Often Did Not Produce Lower Prices For Antiretrovirals Compared To International Procurement. Health Affairs.
Beall R, Kuhn R, Attaran A (2015) Compulsory Licenses: The Authors Reply. Health Affairs.
Beall R, Nickerson J, Attaran A (2014) Pan-Canadian Medicine Overpricing: A Five-Country Study of Generic Medicine Cost Control. Open Medicine.
Attaran A, Beall R (2014). Internet Pharmacies: Canada’s Transnational Organized Crime. Health Law in Canada.
Beall R, Baskerville N, Golfam M, Saeed S, Little J (2014) Modes of Delivery in Preventive Intervention Studies: A Rapid Review. European Journal of Clinical Investigation.
Saeed S, Golfam M, Beall R, Little J (2014) Effectiveness of individual-focused interventions to prevent chronic disease. European Journal of Clinical Investigation.
Golfam M, Saeed S, Beall R, Little J (2014) Comparing alternative design options for chronic disease prevention interventions. European Journal of Clinical Investigation.
Kuhn R, Beall R (2012) The Time for Pharmaceutical Compulsory Licensing has Expired. Nature Medicine 18(8), 1168. doi:10.1038/nm0812-1168
Beall R, Kuhn R (2012) Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis. PLoS Medicine.